An Adaptive Design for Identifying the Dose with the Best Efficacy/Tolerability Profile with Application to a Crossover Dose-Finding Study

Por Ivanova, Anastasia, Liu, Ken, Snyder, Ellen, Snavely, Duane
Publicado em 2009

Effect of Gaboxadol on Patient-reported Measures of Sleep and Waking Function in Patients with Primary Insomnia: Results from Two Randomized, Controlled, 3-month Studies

Por Roth, Thomas, Lines, Christopher, Vandormael, Kristel, Ceesay, Paulette, Anderson, Donald, Snavely, Duane
Publicado em 2010

Effect of Gaboxadol on Sleep in Adult and Elderly Patients with Primary Insomnia: Results From Two Randomized, Placebo-Controlled, 30-Night Polysomnography Studies

Por Lankford, D. Alan, Corser, Bruce C., Zheng, Yan-Ping, Li, Zhengrong, Snavely, Duane B., Lines, Christopher R., Deacon, Steve
Publicado em 2008

A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia

Por Connor, Kathryn M., Mahoney, Erin, Jackson, Saheeda, Hutzelmann, Jill, Zhao, Xin, Jia, Nan, Snyder, Ellen, Snavely, Duane, Michelson, David, Roth, Thomas, Herring, W. Joseph
Publicado no Int J Neuropsychopharmacol (2016)

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder

Por Connor, Kathryn M, Ceesay, Paulette, Hutzelmann, Jill, Snavely, Duane, Krystal, Andrew D, Trivedi, Madhukar H, Thase, Michael, Lines, Christopher, Herring, W Joseph, Michelson, David
Publicado no Int J Neuropsychopharmacol (2017)

Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials

Por Herring, W. Joseph, Connor, Kathleen M., Snyder, Ellen, Snavely, Duane B., Zhang, Ying, Hutzelmann, Jill, Matzura-Wolfe, Deborah, Benca, Ruth M., Krystal, Andrew D., Walsh, James K., Lines, Christopher, Roth, Thomas, Michelson, David
Publicado no J Clin Sleep Med (2016)